366 related articles for article (PubMed ID: 11281499)
41. Intravenous zoledronic acid 5 mg in the treatment of postmenopausal women with low bone density previously treated with alendronate.
McClung M; Recker R; Miller P; Fiske D; Minkoff J; Kriegman A; Zhou W; Adera M; Davis J
Bone; 2007 Jul; 41(1):122-8. PubMed ID: 17468062
[TBL] [Abstract][Full Text] [Related]
42. A controlled trial of raloxifene (LY139481) HCl: impact on bone turnover and serum lipid profile in healthy postmenopausal women.
Draper MW; Flowers DE; Huster WJ; Neild JA; Harper KD; Arnaud C
J Bone Miner Res; 1996 Jun; 11(6):835-42. PubMed ID: 8725181
[TBL] [Abstract][Full Text] [Related]
43. Effects of transdermal estradiol delivered by a matrix patch on bone density in hysterectomized, postmenopausal women: a 2-year placebo-controlled trial.
Arrenbrecht S; Boermans AJ
Osteoporos Int; 2002; 13(2):176-83. PubMed ID: 11908492
[TBL] [Abstract][Full Text] [Related]
44. Hormone therapy in women in the menopause transition. Randomised, double-blind, placebo-controlled trial of effects on body weight, blood pressure, lipoprotein levels, antithrombin III activity, and the endometrium.
Khoo SK; Coglan MJ; Wright GR; DeVoss KN; Battistutta D
Med J Aust; 1998 Mar; 168(5):216-20. PubMed ID: 9539899
[TBL] [Abstract][Full Text] [Related]
45. Effects of raloxifene on bone mineral density, serum cholesterol concentrations, and uterine endometrium in postmenopausal women.
Delmas PD; Bjarnason NH; Mitlak BH; Ravoux AC; Shah AS; Huster WJ; Draper M; Christiansen C
N Engl J Med; 1997 Dec; 337(23):1641-7. PubMed ID: 9385122
[TBL] [Abstract][Full Text] [Related]
46. Two new combinations of estrogen and progestogen for prevention of postmenopausal bone loss: long-term effects on bone, calcium and lipid metabolism, climacteric symptoms, and bleeding.
Marslew U; Overgaard K; Riis BJ; Christiansen C
Obstet Gynecol; 1992 Feb; 79(2):202-10. PubMed ID: 1309944
[TBL] [Abstract][Full Text] [Related]
47. Raloxifene lowers serum lipoprotein(A) in healthy postmenopausal women: a randomized, double-blind, placebo-controlled comparison with conjugated equine estrogens.
Mijatovic V; van der Mooren MJ; Kenemans P; de Valk-de Roo GW; Netelenbos C
Menopause; 1999; 6(2):134-7. PubMed ID: 10374220
[TBL] [Abstract][Full Text] [Related]
48. Effects of isoflavone and exercise on BMD and fat mass in postmenopausal Japanese women: a 1-year randomized placebo-controlled trial.
Wu J; Oka J; Tabata I; Higuchi M; Toda T; Fuku N; Ezaki J; Sugiyama F; Uchiyama S; Yamada K; Ishimi Y
J Bone Miner Res; 2006 May; 21(5):780-9. PubMed ID: 16734394
[TBL] [Abstract][Full Text] [Related]
49. [Comparison of the effectiveness of 17-beta-estradiol and calcitonin in women with postmenopausal bone loss].
Stĕpán J; Formánková J; Masatová A; Michalský M; Rosenová Z
Cas Lek Cesk; 1997 Apr; 136(8):242-8. PubMed ID: 9264868
[TBL] [Abstract][Full Text] [Related]
50. Effect of oral estradiol on Lp(a) and other lipoproteins in postmenopausal women. A randomized, double-blind, placebo-controlled, crossover study.
Haines C; Chung T; Chang A; Masarei J; Tomlinson B; Wong E
Arch Intern Med; 1996 Apr; 156(8):866-72. PubMed ID: 8774205
[TBL] [Abstract][Full Text] [Related]
51. Hormonal and metabolic effects of transdermal estradiol/progestagen administration in postmenopausal women.
Perrone G; Falaschi P; Capri O; Pastore R; Galoppi P; D'Urso R; Martocchia A; Anelli G; Zichella L
Int J Fertil Menopausal Stud; 1994; 39(4):202-7. PubMed ID: 7951402
[TBL] [Abstract][Full Text] [Related]
52. Prevention of postmenopausal osteoporosis. A comparative study of exercise, calcium supplementation, and hormone-replacement therapy.
Prince RL; Smith M; Dick IM; Price RI; Webb PG; Henderson NK; Harris MM
N Engl J Med; 1991 Oct; 325(17):1189-95. PubMed ID: 1922205
[TBL] [Abstract][Full Text] [Related]
53. Hormone replacement therapy increases trabecular and cortical bone density in osteoporotic women.
Bagur A; Wittich A; Ghiringhelli G; Vega E; Mautalen C
Medicina (B Aires); 1996; 56(3):247-51. PubMed ID: 9035480
[TBL] [Abstract][Full Text] [Related]
54. Prospective double-blind study of CEE3 in peri- and postmenopausal women: effects on bone loss and lipoprotein lipids.
Cheng GJ; Liu JL; Zhang Q; Ye HF; Wang ZQ; Pan HP
Chin Med J (Engl); 1992 Nov; 105(11):929-33. PubMed ID: 1304463
[TBL] [Abstract][Full Text] [Related]
55. An estradiol matrix transdermal system for the prevention of postmenopausal bone loss.
McKeever C; McIlwain H; Greenwald M; Gupta N; Jayawardene S; Huels G; Roberts M
Clin Ther; 2000 Jul; 22(7):845-57. PubMed ID: 10945511
[TBL] [Abstract][Full Text] [Related]
56. Effects of genistein and hormone-replacement therapy on bone loss in early postmenopausal women: a randomized double-blind placebo-controlled study.
Morabito N; Crisafulli A; Vergara C; Gaudio A; Lasco A; Frisina N; D'Anna R; Corrado F; Pizzoleo MA; Cincotta M; Altavilla D; Ientile R; Squadrito F
J Bone Miner Res; 2002 Oct; 17(10):1904-12. PubMed ID: 12369794
[TBL] [Abstract][Full Text] [Related]
57. Long-term effects of continuous combined HRT on bone turnover and lipid metabolism in postmenopausal women.
Hart DM; Farish E; Fletcher CD; Barnes JF; Hart H; Nolan D; Spowart K
Osteoporos Int; 1998; 8(4):326-32. PubMed ID: 10024902
[TBL] [Abstract][Full Text] [Related]
58. Use of low-dosage 17 beta-estradiol for the prevention of osteoporosis.
Ettinger B
Clin Ther; 1993; 15(6):950-62; discussion 949. PubMed ID: 8111815
[TBL] [Abstract][Full Text] [Related]
59. The prevention of bone loss in young women treated with GnRH analogues with "add-back" estrogen therapy.
Leather AT; Studd JW; Watson NR; Holland EF
Obstet Gynecol; 1993 Jan; 81(1):104-7. PubMed ID: 8416441
[TBL] [Abstract][Full Text] [Related]
60. 17 Beta-estradiol and continuous norethisterone: a unique treatment for established osteoporosis in elderly women.
Christiansen C; Riis BJ
J Clin Endocrinol Metab; 1990 Oct; 71(4):836-41. PubMed ID: 2205624
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
